BMO Capital Markets reaffirmed their outperform rating on shares of Flexion Therapeutics, Inc. (NASDAQ:FLXN) in a report released on Monday. BMO Capital Markets currently has a $37.00 price objective on the specialty pharmaceutical company’s stock, up from their prior price objective of $35.00.
Other research analysts also recently issued research reports about the stock. Zacks Investment Research upgraded shares of Flexion Therapeutics from a sell rating to a hold rating in a research report on Monday, August 28th. Needham & Company LLC reiterated a buy rating and set a $36.00 target price (up previously from $34.00) on shares of Flexion Therapeutics in a research report on Thursday, August 10th. Cantor Fitzgerald set a $40.00 target price on shares of Flexion Therapeutics and gave the company a buy rating in a research report on Monday, June 12th. Janney Montgomery Scott restated a buy rating and set a $35.00 price objective (up previously from $30.00) on shares of Flexion Therapeutics in a report on Wednesday, July 12th. Finally, ValuEngine upgraded shares of Flexion Therapeutics from a sell rating to a hold rating in a report on Wednesday, June 21st. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $88.50.
Shares of Flexion Therapeutics (NASDAQ:FLXN) traded up 1.68% during midday trading on Monday, hitting $26.65. 3,436,353 shares of the company were exchanged. Flexion Therapeutics has a one year low of $15.93 and a one year high of $32.25. The firm’s market capitalization is $850.27 million. The firm’s 50 day moving average price is $25.08 and its 200 day moving average price is $22.65.
Flexion Therapeutics (NASDAQ:FLXN) last released its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.80) by ($0.11). Analysts forecast that Flexion Therapeutics will post ($3.78) EPS for the current fiscal year.
WARNING: “Flexion Therapeutics, Inc. (FLXN) Earns “Outperform” Rating from BMO Capital Markets” was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.themarketsdaily.com/2017/10/12/flexion-therapeutics-inc-flxn-earns-outperform-rating-from-bmo-capital-markets.html.
In other Flexion Therapeutics news, insider Yamo Deniz acquired 3,000 shares of the stock in a transaction on Friday, September 1st. The shares were purchased at an average price of $24.15 per share, for a total transaction of $72,450.00. Following the completion of the acquisition, the insider now owns 5,000 shares in the company, valued at approximately $120,750. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last 90 days, insiders have acquired 5,375 shares of company stock worth $131,575. Corporate insiders own 15.98% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Fiduciary Trust Co. acquired a new position in Flexion Therapeutics during the second quarter worth $101,000. IFP Advisors Inc raised its holdings in shares of Flexion Therapeutics by 24.5% in the second quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock valued at $103,000 after purchasing an additional 1,000 shares during the last quarter. Advisor Group Inc. raised its holdings in shares of Flexion Therapeutics by 205.9% in the second quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock valued at $105,000 after purchasing an additional 3,500 shares during the last quarter. Asset Management One Co. Ltd. purchased a new stake in shares of Flexion Therapeutics in the first quarter valued at about $319,000. Finally, Voya Investment Management LLC raised its holdings in shares of Flexion Therapeutics by 25.8% in the second quarter. Voya Investment Management LLC now owns 12,914 shares of the specialty pharmaceutical company’s stock valued at $261,000 after purchasing an additional 2,651 shares during the last quarter. Hedge funds and other institutional investors own 83.26% of the company’s stock.
About Flexion Therapeutics
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.